QUIDE
LOE Approachingpiperacetazine
NDAORALTABLET
Approved
Feb 1969
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 20h ago · AI intelligence enriched 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
QUIDE (piperacetazine) is an oral tablet antipsychotic approved in 1969 for schizophrenia and related psychotic disorders. The drug mechanism and specific indications are not documented in available data, reflecting its age and legacy status in the psychiatric medication portfolio.
LOE Approaching
With LOE approaching, the QUIDE brand team is likely in maintenance mode with reduced headcount focused on managing generic transition and minimizing revenue erosion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
QUIDE offers minimal career growth opportunity as a legacy product approaching loss of exclusivity with zero linked job postings. Roles tied to this asset focus on defensive strategies, cost management, and managed care positioning rather than innovation or market expansion.
Generic Strategy ManagerField Sales
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.